<?xml version="1.0"?>
<rss version="2.0">
 <channel>
  <title>StreetInsider.com News Articles</title>
  <link>http://www.streetinsider.com</link>
  <description>Latest StreetInsider.com News Articles</description>
  <language>en-us</language>
  <copyright>Copyright 2026, StreetInsider.com</copyright>
  <managingEditor>rss@streetinsider.com (SI RSS)</managingEditor>
  <webMaster>rss@streetinsider.com (SI RSS)</webMaster>
  <lastBuildDate>Tue, 07 Jul 2026 08:37:10 -0400</lastBuildDate>
  <docs>http://blogs.law.harvard.edu/tech/rss</docs>
  <image>
   <url>http://www.streetinsider.com/images/rss_logo.gif</url>
   <title>StreetInsider.com News Articles</title>
   <link>http://www.streetinsider.com</link>
   <width>143</width>
   <height>28</height>
  </image>
  <skipHours>
   <hour>0</hour>
   <hour>1</hour>
   <hour>2</hour>
   <hour>3</hour>
   <hour>21</hour>
   <hour>22</hour>
   <hour>23</hour>
  </skipHours>
  <skipDays>
   <day>Saturday</day>
   <day>Sunday</day>
  </skipDays>
  <item>
   <title>Carlisle (CSL) PT Lowered to $340 at Truist on 'Input Cost Inflation'</title>
   <link>http://www.streetinsider.com/Analyst+PT+Change/Carlisle+%28CSL%29+PT+Lowered+to+%24340+at+Truist+on+%27Input+Cost+Inflation%27/26738272.html</link>
   <description>(Updated - July 7, 2026 8:37 AM EDT)

&lt;p&gt;Truist Securities analyst Keith Hughes lowered the price target on Carlisle (NYSE: CSL) to $340.00 (from $360.00) while maintaining a Hold rating.&lt;/p&gt;&lt;p&gt;The analyst commented: &quot;Lowering Estimates and Price Target to $340 on Input Cost Inflation; The commercial roofing industry is facing significant cost inflation driven by higher petrochemical prices and supply disruptions in MDI, a key raw material, following manufacturing issues from major suppliers. In response, CSL and peers have implemented multiple price increases, though these are expected to lag rising costs and pressure margins through the rest of 2026. Longer term, investors</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Analyst+PT+Change/Carlisle+%28CSL%29+PT+Lowered+to+%24340+at+Truist+on+%27Input+Cost+Inflation%27/26738272.html</guid>
   <pubDate>Tue, 07 Jul 2026 08:37:10 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">CSL</category>
   	  </item>
  <item>
   <title>Carlisle (CSL) PT Lowered to $340 at Truist on 'Input Cost Inflation'</title>
   <link>http://www.streetinsider.com/Analyst+Comments/Carlisle+%28CSL%29+PT+Lowered+to+%24340+at+Truist+on+%27Input+Cost+Inflation%27/26738272.html</link>
   <description>(Updated - July 7, 2026 8:37 AM EDT)

&lt;p&gt;Truist Securities analyst Keith Hughes lowered the price target on Carlisle (NYSE: CSL) to $340.00 (from $360.00) while maintaining a Hold rating.&lt;/p&gt;&lt;p&gt;The analyst commented: &quot;Lowering Estimates and Price Target to $340 on Input Cost Inflation; The commercial roofing industry is facing significant cost inflation driven by higher petrochemical prices and supply disruptions in MDI, a key raw material, following manufacturing issues from major suppliers. In response, CSL and peers have implemented multiple price increases, though these are expected to lag rising costs and pressure margins through the rest of 2026. Longer term, investors</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Analyst+Comments/Carlisle+%28CSL%29+PT+Lowered+to+%24340+at+Truist+on+%27Input+Cost+Inflation%27/26738272.html</guid>
   <pubDate>Tue, 07 Jul 2026 08:37:10 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">CSL</category>
   	  </item>
  <item>
   <title>Owens Corning shares jump on Carlisle bid report</title>
   <link>http://www.streetinsider.com/Investing/Owens+Corning+shares+jump+on+Carlisle+bid+report/26704985.html</link>
   <description>&lt;p&gt;Investing.com -- Owens Corning shares rose nearly 9% at midday on Monday, reversing earlier losses, after the Wall Street Journal reported that Carlisle made unsolicited offers to acquire the company.&lt;/p&gt;&lt;p&gt;Construction-products supplier Carlisle reportedly approached rival Owens Corning with takeover proposals. Owens Corning has not engaged substantially regarding a potential deal, WSJ said.&lt;/p&gt;&lt;p&gt;Carlisle Companies shares fell 5% following the report. &lt;/p&gt;</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Investing/Owens+Corning+shares+jump+on+Carlisle+bid+report/26704985.html</guid>
   <pubDate>Mon, 29 Jun 2026 13:10:48 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">CSL</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">OC</category>
   	  </item>
  <item>
   <title>Owens Corning shares jump on Carlisle bid report</title>
   <link>http://www.streetinsider.com/Investing/Owens+Corning+shares+jump+on+Carlisle+bid+report/26704985.html</link>
   <description>&lt;p&gt;Investing.com -- Owens Corning shares rose nearly 9% at midday on Monday, reversing earlier losses, after the Wall Street Journal reported that Carlisle made unsolicited offers to acquire the company.&lt;/p&gt;&lt;p&gt;Construction-products supplier Carlisle reportedly approached rival Owens Corning with takeover proposals. Owens Corning has not engaged substantially regarding a potential deal, WSJ said.&lt;/p&gt;&lt;p&gt;Carlisle Companies shares fell 5% following the report. &lt;/p&gt;</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Investing/Owens+Corning+shares+jump+on+Carlisle+bid+report/26704985.html</guid>
   <pubDate>Mon, 29 Jun 2026 13:10:48 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">CSL</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">OC</category>
   	  </item>
  <item>
   <title>Carlisle Made Unsolicited Offers for Rival Owens Corning - WSJ</title>
   <link>http://www.streetinsider.com/Hot+M+and+A/Carlisle+Made+Unsolicited+Offers+for+Rival+Owens+Corning+-+WSJ/26704942.html</link>
   <description>(Updated - June 29, 2026 1:06 PM EDT)

&lt;p&gt;Construction-products supplier Carlisle made unsolicited offers for rival Owens Corning - WSJ&lt;/p&gt;&lt;ul&gt;&lt;li&gt;Owens Corning reportedly hasn't engaged substantially about potential deal.&lt;/li&gt;&lt;/ul&gt;</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Hot+M+and+A/Carlisle+Made+Unsolicited+Offers+for+Rival+Owens+Corning+-+WSJ/26704942.html</guid>
   <pubDate>Mon, 29 Jun 2026 13:06:17 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">CSL</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">OC</category>
   	  </item>
  <item>
   <title>Carlisle Made Unsolicited Offers for Rival Owens Corning - WSJ</title>
   <link>http://www.streetinsider.com/Hot+M+and+A/Carlisle+Made+Unsolicited+Offers+for+Rival+Owens+Corning+-+WSJ/26704942.html</link>
   <description>(Updated - June 29, 2026 1:06 PM EDT)

&lt;p&gt;Construction-products supplier Carlisle made unsolicited offers for rival Owens Corning - WSJ&lt;/p&gt;&lt;ul&gt;&lt;li&gt;Owens Corning reportedly hasn't engaged substantially about potential deal.&lt;/li&gt;&lt;/ul&gt;</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Hot+M+and+A/Carlisle+Made+Unsolicited+Offers+for+Rival+Owens+Corning+-+WSJ/26704942.html</guid>
   <pubDate>Mon, 29 Jun 2026 13:06:17 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">CSL</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">OC</category>
   	  </item>
  <item>
   <title>Carlisle Made Unsolicited Offers for Rival Owens Corning - WSJ</title>
   <link>http://www.streetinsider.com/Rumors/Carlisle+Made+Unsolicited+Offers+for+Rival+Owens+Corning+-+WSJ/26704942.html</link>
   <description>(Updated - June 29, 2026 1:06 PM EDT)

&lt;p&gt;Construction-products supplier Carlisle made unsolicited offers for rival Owens Corning - WSJ&lt;/p&gt;&lt;ul&gt;&lt;li&gt;Owens Corning reportedly hasn't engaged substantially about potential deal.&lt;/li&gt;&lt;/ul&gt;</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Rumors/Carlisle+Made+Unsolicited+Offers+for+Rival+Owens+Corning+-+WSJ/26704942.html</guid>
   <pubDate>Mon, 29 Jun 2026 13:06:17 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">CSL</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">OC</category>
   	  </item>
  <item>
   <title>Carlisle Made Unsolicited Offers for Rival Owens Corning - WSJ</title>
   <link>http://www.streetinsider.com/Rumors/Carlisle+Made+Unsolicited+Offers+for+Rival+Owens+Corning+-+WSJ/26704942.html</link>
   <description>(Updated - June 29, 2026 1:06 PM EDT)

&lt;p&gt;Construction-products supplier Carlisle made unsolicited offers for rival Owens Corning - WSJ&lt;/p&gt;&lt;ul&gt;&lt;li&gt;Owens Corning reportedly hasn't engaged substantially about potential deal.&lt;/li&gt;&lt;/ul&gt;</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Rumors/Carlisle+Made+Unsolicited+Offers+for+Rival+Owens+Corning+-+WSJ/26704942.html</guid>
   <pubDate>Mon, 29 Jun 2026 13:06:17 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">CSL</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">OC</category>
   	  </item>
  <item>
   <title>Carlisle Made Unsolicited Offers for Rival Owens Corning - WSJ</title>
   <link>http://www.streetinsider.com/Mergers+and+Acquisitions/Carlisle+Made+Unsolicited+Offers+for+Rival+Owens+Corning+-+WSJ/26704942.html</link>
   <description>(Updated - June 29, 2026 1:06 PM EDT)

&lt;p&gt;Construction-products supplier Carlisle made unsolicited offers for rival Owens Corning - WSJ&lt;/p&gt;&lt;ul&gt;&lt;li&gt;Owens Corning reportedly hasn't engaged substantially about potential deal.&lt;/li&gt;&lt;/ul&gt;</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Mergers+and+Acquisitions/Carlisle+Made+Unsolicited+Offers+for+Rival+Owens+Corning+-+WSJ/26704942.html</guid>
   <pubDate>Mon, 29 Jun 2026 13:06:17 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">CSL</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">OC</category>
   	  </item>
  <item>
   <title>Carlisle Made Unsolicited Offers for Rival Owens Corning - WSJ</title>
   <link>http://www.streetinsider.com/Mergers+and+Acquisitions/Carlisle+Made+Unsolicited+Offers+for+Rival+Owens+Corning+-+WSJ/26704942.html</link>
   <description>(Updated - June 29, 2026 1:06 PM EDT)

&lt;p&gt;Construction-products supplier Carlisle made unsolicited offers for rival Owens Corning - WSJ&lt;/p&gt;&lt;ul&gt;&lt;li&gt;Owens Corning reportedly hasn't engaged substantially about potential deal.&lt;/li&gt;&lt;/ul&gt;</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Mergers+and+Acquisitions/Carlisle+Made+Unsolicited+Offers+for+Rival+Owens+Corning+-+WSJ/26704942.html</guid>
   <pubDate>Mon, 29 Jun 2026 13:06:17 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">CSL</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">OC</category>
   	  </item>
  <item>
   <title>Carlisle Made Unsolicited Offers for Rival Owens Corning - WSJ</title>
   <link>http://www.streetinsider.com/Trader+Talk/Carlisle+Made+Unsolicited+Offers+for+Rival+Owens+Corning+-+WSJ/26704942.html</link>
   <description>(Updated - June 29, 2026 1:06 PM EDT)

&lt;p&gt;Construction-products supplier Carlisle made unsolicited offers for rival Owens Corning - WSJ&lt;/p&gt;&lt;ul&gt;&lt;li&gt;Owens Corning reportedly hasn't engaged substantially about potential deal.&lt;/li&gt;&lt;/ul&gt;</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Trader+Talk/Carlisle+Made+Unsolicited+Offers+for+Rival+Owens+Corning+-+WSJ/26704942.html</guid>
   <pubDate>Mon, 29 Jun 2026 13:06:17 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">CSL</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">OC</category>
   	  </item>
  <item>
   <title>Carlisle Made Unsolicited Offers for Rival Owens Corning - WSJ</title>
   <link>http://www.streetinsider.com/Trader+Talk/Carlisle+Made+Unsolicited+Offers+for+Rival+Owens+Corning+-+WSJ/26704942.html</link>
   <description>(Updated - June 29, 2026 1:06 PM EDT)

&lt;p&gt;Construction-products supplier Carlisle made unsolicited offers for rival Owens Corning - WSJ&lt;/p&gt;&lt;ul&gt;&lt;li&gt;Owens Corning reportedly hasn't engaged substantially about potential deal.&lt;/li&gt;&lt;/ul&gt;</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Trader+Talk/Carlisle+Made+Unsolicited+Offers+for+Rival+Owens+Corning+-+WSJ/26704942.html</guid>
   <pubDate>Mon, 29 Jun 2026 13:06:17 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">CSL</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">OC</category>
   	  </item>
  <item>
   <title>EU panel recommends revoking Tavneos marketing authorization</title>
   <link>http://www.streetinsider.com/FDA/EU+panel+recommends+revoking+Tavneos+marketing+authorization/26695552.html</link>
   <description>&lt;p&gt;The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has recommended revoking the European Union marketing authorization for TAVNEOS (avacopan), a treatment for adults with severe, active granulomatosis with polyangiitis or microscopic polyangiitis, the main forms of ANCA-associated vasculitis.&lt;/p&gt;&lt;p&gt;The recommendation, disclosed by Vifor Fresenius Medical Care Renal Pharma (VFMCRP) and CSL (ASX: CSL; USOTC: CSLLY), follows an Article 20 non-pharmacovigilance procedure initiated due to concerns related to data handling in the pivotal Phase 3 ADVOCATE trial, which supported the drug's original approval.&lt;/p&gt;&lt;p&gt;The CHMP opinion has been forwarded to the European Commission, which is expected to issue a</description>
   <guid isPermaLink="true">http://www.streetinsider.com/FDA/EU+panel+recommends+revoking+Tavneos+marketing+authorization/26695552.html</guid>
   <pubDate>Fri, 26 Jun 2026 09:02:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">CSL</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">CSLLY</category>
   	  </item>
  <item>
   <title>EU panel recommends revoking Tavneos marketing authorization</title>
   <link>http://www.streetinsider.com/FDA/EU+panel+recommends+revoking+Tavneos+marketing+authorization/26695552.html</link>
   <description>&lt;p&gt;The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has recommended revoking the European Union marketing authorization for TAVNEOS (avacopan), a treatment for adults with severe, active granulomatosis with polyangiitis or microscopic polyangiitis, the main forms of ANCA-associated vasculitis.&lt;/p&gt;&lt;p&gt;The recommendation, disclosed by Vifor Fresenius Medical Care Renal Pharma (VFMCRP) and CSL (ASX: CSL; USOTC: CSLLY), follows an Article 20 non-pharmacovigilance procedure initiated due to concerns related to data handling in the pivotal Phase 3 ADVOCATE trial, which supported the drug's original approval.&lt;/p&gt;&lt;p&gt;The CHMP opinion has been forwarded to the European Commission, which is expected to issue a</description>
   <guid isPermaLink="true">http://www.streetinsider.com/FDA/EU+panel+recommends+revoking+Tavneos+marketing+authorization/26695552.html</guid>
   <pubDate>Fri, 26 Jun 2026 09:02:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">CSL</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">CSLLY</category>
   	  </item>
  <item>
   <title>CHMP recommends revoking marketing authorisation for TAVNEOS® (avacopan) in the European Union</title>
   <link>http://www.streetinsider.com/Press+Releases/CHMP+recommends+revoking+marketing+authorisation+for+TAVNEOS%C2%AE+%28avacopan%29+in+the+European+Union/26695514.html</link>
   <description>
&lt;div class=&quot;xn-content&quot;&gt;
&lt;ul type=&quot;disc&quot;&gt;&lt;li&gt;Recommendation follows an Article 20 non-pharmacovigilance procedure &lt;/li&gt;&lt;li&gt;Patients currently on TAVNEOS treatment should consult their treating physician  &lt;/li&gt;&lt;/ul&gt;&lt;p&gt;&lt;span class=&quot;legendSpanClass&quot;&gt;&lt;person&gt;ST. GALLEN&lt;/person&gt;, &lt;location value=&quot;LC/ch&quot; idsrc=&quot;xmltag.org&quot; &gt;Switzerland&lt;/location&gt;&lt;/span&gt;, &lt;span class=&quot;legendSpanClass&quot;&gt;&lt;chron&gt;June 26, 2026&lt;/chron&gt;&lt;/span&gt; /PRNewswire/ -- &lt;span value=&quot;ACORN:4004701974&quot; idsrc=&quot;xmltag.org&quot; &gt;Vifor Fresenius Medical Care Renal Pharma&lt;/span&gt; (VFMCRP) and CSL announced today that the &lt;span value=&quot;ACORN:3106670068&quot; idsrc=&quot;xmltag.org&quot; &gt;European Medicines Agency's&lt;/span&gt; (EMA) &lt;span&gt;Committee for Medicinal Products&lt;/span&gt; for Human Use (CHMP) has recommended the revocation of the &lt;span&gt;European Union&lt;/span&gt; (EU) marketing authorisation for TAVNEOS® (avacopan). TAVNEOS is a treatment for adults with severe, active granulomatosis with polyangiitis (GPA) or microscopic polyangiitis (MPA), which are the main forms of ANCA-associated vasculitis. TAVNEOS</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Press+Releases/CHMP+recommends+revoking+marketing+authorisation+for+TAVNEOS%C2%AE+%28avacopan%29+in+the+European+Union/26695514.html</guid>
   <pubDate>Fri, 26 Jun 2026 09:00:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">A.01699993</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.31066700</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.37879753</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.40047019</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.60012004</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">CSL</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">CSLLY</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.00185691</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.00222426</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.00673957</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.01304637</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.09767912</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.22422661</category>
   	  </item>
  <item>
   <title>CHMP recommends revoking marketing authorisation for TAVNEOS® (avacopan) in the European Union</title>
   <link>http://www.streetinsider.com/Press+Releases/CHMP+recommends+revoking+marketing+authorisation+for+TAVNEOS%C2%AE+%28avacopan%29+in+the+European+Union/26695514.html</link>
   <description>
&lt;div class=&quot;xn-content&quot;&gt;
&lt;ul type=&quot;disc&quot;&gt;&lt;li&gt;Recommendation follows an Article 20 non-pharmacovigilance procedure &lt;/li&gt;&lt;li&gt;Patients currently on TAVNEOS treatment should consult their treating physician  &lt;/li&gt;&lt;/ul&gt;&lt;p&gt;&lt;span class=&quot;legendSpanClass&quot;&gt;&lt;person&gt;ST. GALLEN&lt;/person&gt;, &lt;location value=&quot;LC/ch&quot; idsrc=&quot;xmltag.org&quot; &gt;Switzerland&lt;/location&gt;&lt;/span&gt;, &lt;span class=&quot;legendSpanClass&quot;&gt;&lt;chron&gt;June 26, 2026&lt;/chron&gt;&lt;/span&gt; /PRNewswire/ -- &lt;span value=&quot;ACORN:4004701974&quot; idsrc=&quot;xmltag.org&quot; &gt;Vifor Fresenius Medical Care Renal Pharma&lt;/span&gt; (VFMCRP) and CSL announced today that the &lt;span value=&quot;ACORN:3106670068&quot; idsrc=&quot;xmltag.org&quot; &gt;European Medicines Agency's&lt;/span&gt; (EMA) &lt;span&gt;Committee for Medicinal Products&lt;/span&gt; for Human Use (CHMP) has recommended the revocation of the &lt;span&gt;European Union&lt;/span&gt; (EU) marketing authorisation for TAVNEOS® (avacopan). TAVNEOS is a treatment for adults with severe, active granulomatosis with polyangiitis (GPA) or microscopic polyangiitis (MPA), which are the main forms of ANCA-associated vasculitis. TAVNEOS</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Press+Releases/CHMP+recommends+revoking+marketing+authorisation+for+TAVNEOS%C2%AE+%28avacopan%29+in+the+European+Union/26695514.html</guid>
   <pubDate>Fri, 26 Jun 2026 09:00:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">A.01699993</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.31066700</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.37879753</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.40047019</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.60012004</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">CSL</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">CSLLY</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.00185691</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.00222426</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.00673957</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.01304637</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.09767912</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.22422661</category>
   	  </item>
  <item>
   <title>CHMP recommends revoking marketing authorisation for TAVNEOS® (avacopan) in the European Union</title>
   <link>http://www.streetinsider.com/Press+Releases/CHMP+recommends+revoking+marketing+authorisation+for+TAVNEOS%C2%AE+%28avacopan%29+in+the+European+Union/26695514.html</link>
   <description>
&lt;div class=&quot;xn-content&quot;&gt;
&lt;ul type=&quot;disc&quot;&gt;&lt;li&gt;Recommendation follows an Article 20 non-pharmacovigilance procedure &lt;/li&gt;&lt;li&gt;Patients currently on TAVNEOS treatment should consult their treating physician  &lt;/li&gt;&lt;/ul&gt;&lt;p&gt;&lt;span class=&quot;legendSpanClass&quot;&gt;&lt;person&gt;ST. GALLEN&lt;/person&gt;, &lt;location value=&quot;LC/ch&quot; idsrc=&quot;xmltag.org&quot; &gt;Switzerland&lt;/location&gt;&lt;/span&gt;, &lt;span class=&quot;legendSpanClass&quot;&gt;&lt;chron&gt;June 26, 2026&lt;/chron&gt;&lt;/span&gt; /PRNewswire/ -- &lt;span value=&quot;ACORN:4004701974&quot; idsrc=&quot;xmltag.org&quot; &gt;Vifor Fresenius Medical Care Renal Pharma&lt;/span&gt; (VFMCRP) and CSL announced today that the &lt;span value=&quot;ACORN:3106670068&quot; idsrc=&quot;xmltag.org&quot; &gt;European Medicines Agency's&lt;/span&gt; (EMA) &lt;span&gt;Committee for Medicinal Products&lt;/span&gt; for Human Use (CHMP) has recommended the revocation of the &lt;span&gt;European Union&lt;/span&gt; (EU) marketing authorisation for TAVNEOS® (avacopan). TAVNEOS is a treatment for adults with severe, active granulomatosis with polyangiitis (GPA) or microscopic polyangiitis (MPA), which are the main forms of ANCA-associated vasculitis. TAVNEOS</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Press+Releases/CHMP+recommends+revoking+marketing+authorisation+for+TAVNEOS%C2%AE+%28avacopan%29+in+the+European+Union/26695514.html</guid>
   <pubDate>Fri, 26 Jun 2026 09:00:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">A.01699993</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.31066700</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.37879753</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.40047019</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.60012004</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">CSL</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">CSLLY</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.00185691</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.00222426</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.00673957</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.01304637</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.09767912</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.22422661</category>
   	  </item>
  <item>
   <title>CHMP recommends revoking marketing authorisation for TAVNEOS® (avacopan) in the European Union</title>
   <link>http://www.streetinsider.com/Press+Releases/CHMP+recommends+revoking+marketing+authorisation+for+TAVNEOS%C2%AE+%28avacopan%29+in+the+European+Union/26695514.html</link>
   <description>
&lt;div class=&quot;xn-content&quot;&gt;
&lt;ul type=&quot;disc&quot;&gt;&lt;li&gt;Recommendation follows an Article 20 non-pharmacovigilance procedure &lt;/li&gt;&lt;li&gt;Patients currently on TAVNEOS treatment should consult their treating physician  &lt;/li&gt;&lt;/ul&gt;&lt;p&gt;&lt;span class=&quot;legendSpanClass&quot;&gt;&lt;person&gt;ST. GALLEN&lt;/person&gt;, &lt;location value=&quot;LC/ch&quot; idsrc=&quot;xmltag.org&quot; &gt;Switzerland&lt;/location&gt;&lt;/span&gt;, &lt;span class=&quot;legendSpanClass&quot;&gt;&lt;chron&gt;June 26, 2026&lt;/chron&gt;&lt;/span&gt; /PRNewswire/ -- &lt;span value=&quot;ACORN:4004701974&quot; idsrc=&quot;xmltag.org&quot; &gt;Vifor Fresenius Medical Care Renal Pharma&lt;/span&gt; (VFMCRP) and CSL announced today that the &lt;span value=&quot;ACORN:3106670068&quot; idsrc=&quot;xmltag.org&quot; &gt;European Medicines Agency's&lt;/span&gt; (EMA) &lt;span&gt;Committee for Medicinal Products&lt;/span&gt; for Human Use (CHMP) has recommended the revocation of the &lt;span&gt;European Union&lt;/span&gt; (EU) marketing authorisation for TAVNEOS® (avacopan). TAVNEOS is a treatment for adults with severe, active granulomatosis with polyangiitis (GPA) or microscopic polyangiitis (MPA), which are the main forms of ANCA-associated vasculitis. TAVNEOS</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Press+Releases/CHMP+recommends+revoking+marketing+authorisation+for+TAVNEOS%C2%AE+%28avacopan%29+in+the+European+Union/26695514.html</guid>
   <pubDate>Fri, 26 Jun 2026 09:00:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">A.01699993</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.31066700</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.37879753</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.40047019</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.60012004</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">CSL</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">CSLLY</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.00185691</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.00222426</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.00673957</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.01304637</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.09767912</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.22422661</category>
   	  </item>
  <item>
   <title>CHMP recommends revoking marketing authorisation for TAVNEOS® (avacopan) in the European Union</title>
   <link>http://www.streetinsider.com/Press+Releases/CHMP+recommends+revoking+marketing+authorisation+for+TAVNEOS%C2%AE+%28avacopan%29+in+the+European+Union/26695514.html</link>
   <description>
&lt;div class=&quot;xn-content&quot;&gt;
&lt;ul type=&quot;disc&quot;&gt;&lt;li&gt;Recommendation follows an Article 20 non-pharmacovigilance procedure &lt;/li&gt;&lt;li&gt;Patients currently on TAVNEOS treatment should consult their treating physician  &lt;/li&gt;&lt;/ul&gt;&lt;p&gt;&lt;span class=&quot;legendSpanClass&quot;&gt;&lt;person&gt;ST. GALLEN&lt;/person&gt;, &lt;location value=&quot;LC/ch&quot; idsrc=&quot;xmltag.org&quot; &gt;Switzerland&lt;/location&gt;&lt;/span&gt;, &lt;span class=&quot;legendSpanClass&quot;&gt;&lt;chron&gt;June 26, 2026&lt;/chron&gt;&lt;/span&gt; /PRNewswire/ -- &lt;span value=&quot;ACORN:4004701974&quot; idsrc=&quot;xmltag.org&quot; &gt;Vifor Fresenius Medical Care Renal Pharma&lt;/span&gt; (VFMCRP) and CSL announced today that the &lt;span value=&quot;ACORN:3106670068&quot; idsrc=&quot;xmltag.org&quot; &gt;European Medicines Agency's&lt;/span&gt; (EMA) &lt;span&gt;Committee for Medicinal Products&lt;/span&gt; for Human Use (CHMP) has recommended the revocation of the &lt;span&gt;European Union&lt;/span&gt; (EU) marketing authorisation for TAVNEOS® (avacopan). TAVNEOS is a treatment for adults with severe, active granulomatosis with polyangiitis (GPA) or microscopic polyangiitis (MPA), which are the main forms of ANCA-associated vasculitis. TAVNEOS</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Press+Releases/CHMP+recommends+revoking+marketing+authorisation+for+TAVNEOS%C2%AE+%28avacopan%29+in+the+European+Union/26695514.html</guid>
   <pubDate>Fri, 26 Jun 2026 09:00:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">A.01699993</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.31066700</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.37879753</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.40047019</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.60012004</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">CSL</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">CSLLY</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.00185691</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.00222426</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.00673957</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.01304637</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.09767912</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.22422661</category>
   	  </item>
  <item>
   <title>CHMP recommends revoking marketing authorisation for TAVNEOS® (avacopan) in the European Union</title>
   <link>http://www.streetinsider.com/Press+Releases/CHMP+recommends+revoking+marketing+authorisation+for+TAVNEOS%C2%AE+%28avacopan%29+in+the+European+Union/26695514.html</link>
   <description>
&lt;div class=&quot;xn-content&quot;&gt;
&lt;ul type=&quot;disc&quot;&gt;&lt;li&gt;Recommendation follows an Article 20 non-pharmacovigilance procedure &lt;/li&gt;&lt;li&gt;Patients currently on TAVNEOS treatment should consult their treating physician  &lt;/li&gt;&lt;/ul&gt;&lt;p&gt;&lt;span class=&quot;legendSpanClass&quot;&gt;&lt;person&gt;ST. GALLEN&lt;/person&gt;, &lt;location value=&quot;LC/ch&quot; idsrc=&quot;xmltag.org&quot; &gt;Switzerland&lt;/location&gt;&lt;/span&gt;, &lt;span class=&quot;legendSpanClass&quot;&gt;&lt;chron&gt;June 26, 2026&lt;/chron&gt;&lt;/span&gt; /PRNewswire/ -- &lt;span value=&quot;ACORN:4004701974&quot; idsrc=&quot;xmltag.org&quot; &gt;Vifor Fresenius Medical Care Renal Pharma&lt;/span&gt; (VFMCRP) and CSL announced today that the &lt;span value=&quot;ACORN:3106670068&quot; idsrc=&quot;xmltag.org&quot; &gt;European Medicines Agency's&lt;/span&gt; (EMA) &lt;span&gt;Committee for Medicinal Products&lt;/span&gt; for Human Use (CHMP) has recommended the revocation of the &lt;span&gt;European Union&lt;/span&gt; (EU) marketing authorisation for TAVNEOS® (avacopan). TAVNEOS is a treatment for adults with severe, active granulomatosis with polyangiitis (GPA) or microscopic polyangiitis (MPA), which are the main forms of ANCA-associated vasculitis. TAVNEOS</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Press+Releases/CHMP+recommends+revoking+marketing+authorisation+for+TAVNEOS%C2%AE+%28avacopan%29+in+the+European+Union/26695514.html</guid>
   <pubDate>Fri, 26 Jun 2026 09:00:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">A.01699993</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.31066700</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.37879753</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.40047019</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.60012004</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">CSL</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">CSLLY</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.00185691</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.00222426</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.00673957</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.01304637</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.09767912</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.22422661</category>
   	  </item>
  <item>
   <title>CHMP recommends revoking marketing authorisation for TAVNEOS® (avacopan) in the European Union</title>
   <link>http://www.streetinsider.com/Press+Releases/CHMP+recommends+revoking+marketing+authorisation+for+TAVNEOS%C2%AE+%28avacopan%29+in+the+European+Union/26695514.html</link>
   <description>
&lt;div class=&quot;xn-content&quot;&gt;
&lt;ul type=&quot;disc&quot;&gt;&lt;li&gt;Recommendation follows an Article 20 non-pharmacovigilance procedure &lt;/li&gt;&lt;li&gt;Patients currently on TAVNEOS treatment should consult their treating physician  &lt;/li&gt;&lt;/ul&gt;&lt;p&gt;&lt;span class=&quot;legendSpanClass&quot;&gt;&lt;person&gt;ST. GALLEN&lt;/person&gt;, &lt;location value=&quot;LC/ch&quot; idsrc=&quot;xmltag.org&quot; &gt;Switzerland&lt;/location&gt;&lt;/span&gt;, &lt;span class=&quot;legendSpanClass&quot;&gt;&lt;chron&gt;June 26, 2026&lt;/chron&gt;&lt;/span&gt; /PRNewswire/ -- &lt;span value=&quot;ACORN:4004701974&quot; idsrc=&quot;xmltag.org&quot; &gt;Vifor Fresenius Medical Care Renal Pharma&lt;/span&gt; (VFMCRP) and CSL announced today that the &lt;span value=&quot;ACORN:3106670068&quot; idsrc=&quot;xmltag.org&quot; &gt;European Medicines Agency's&lt;/span&gt; (EMA) &lt;span&gt;Committee for Medicinal Products&lt;/span&gt; for Human Use (CHMP) has recommended the revocation of the &lt;span&gt;European Union&lt;/span&gt; (EU) marketing authorisation for TAVNEOS® (avacopan). TAVNEOS is a treatment for adults with severe, active granulomatosis with polyangiitis (GPA) or microscopic polyangiitis (MPA), which are the main forms of ANCA-associated vasculitis. TAVNEOS</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Press+Releases/CHMP+recommends+revoking+marketing+authorisation+for+TAVNEOS%C2%AE+%28avacopan%29+in+the+European+Union/26695514.html</guid>
   <pubDate>Fri, 26 Jun 2026 09:00:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">A.01699993</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.31066700</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.37879753</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.40047019</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.60012004</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">CSL</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">CSLLY</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.00185691</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.00222426</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.00673957</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.01304637</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.09767912</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.22422661</category>
   	  </item>
  <item>
   <title>CHMP recommends revoking marketing authorisation for TAVNEOS® (avacopan) in the European Union</title>
   <link>http://www.streetinsider.com/Press+Releases/CHMP+recommends+revoking+marketing+authorisation+for+TAVNEOS%C2%AE+%28avacopan%29+in+the+European+Union/26695514.html</link>
   <description>
&lt;div class=&quot;xn-content&quot;&gt;
&lt;ul type=&quot;disc&quot;&gt;&lt;li&gt;Recommendation follows an Article 20 non-pharmacovigilance procedure &lt;/li&gt;&lt;li&gt;Patients currently on TAVNEOS treatment should consult their treating physician  &lt;/li&gt;&lt;/ul&gt;&lt;p&gt;&lt;span class=&quot;legendSpanClass&quot;&gt;&lt;person&gt;ST. GALLEN&lt;/person&gt;, &lt;location value=&quot;LC/ch&quot; idsrc=&quot;xmltag.org&quot; &gt;Switzerland&lt;/location&gt;&lt;/span&gt;, &lt;span class=&quot;legendSpanClass&quot;&gt;&lt;chron&gt;June 26, 2026&lt;/chron&gt;&lt;/span&gt; /PRNewswire/ -- &lt;span value=&quot;ACORN:4004701974&quot; idsrc=&quot;xmltag.org&quot; &gt;Vifor Fresenius Medical Care Renal Pharma&lt;/span&gt; (VFMCRP) and CSL announced today that the &lt;span value=&quot;ACORN:3106670068&quot; idsrc=&quot;xmltag.org&quot; &gt;European Medicines Agency's&lt;/span&gt; (EMA) &lt;span&gt;Committee for Medicinal Products&lt;/span&gt; for Human Use (CHMP) has recommended the revocation of the &lt;span&gt;European Union&lt;/span&gt; (EU) marketing authorisation for TAVNEOS® (avacopan). TAVNEOS is a treatment for adults with severe, active granulomatosis with polyangiitis (GPA) or microscopic polyangiitis (MPA), which are the main forms of ANCA-associated vasculitis. TAVNEOS</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Press+Releases/CHMP+recommends+revoking+marketing+authorisation+for+TAVNEOS%C2%AE+%28avacopan%29+in+the+European+Union/26695514.html</guid>
   <pubDate>Fri, 26 Jun 2026 09:00:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">A.01699993</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.31066700</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.37879753</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.40047019</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.60012004</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">CSL</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">CSLLY</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.00185691</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.00222426</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.00673957</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.01304637</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.09767912</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.22422661</category>
   	  </item>
  <item>
   <title>CHMP recommends revoking marketing authorisation for TAVNEOS® (avacopan) in the European Union</title>
   <link>http://www.streetinsider.com/Press+Releases/CHMP+recommends+revoking+marketing+authorisation+for+TAVNEOS%C2%AE+%28avacopan%29+in+the+European+Union/26695514.html</link>
   <description>
&lt;div class=&quot;xn-content&quot;&gt;
&lt;ul type=&quot;disc&quot;&gt;&lt;li&gt;Recommendation follows an Article 20 non-pharmacovigilance procedure &lt;/li&gt;&lt;li&gt;Patients currently on TAVNEOS treatment should consult their treating physician  &lt;/li&gt;&lt;/ul&gt;&lt;p&gt;&lt;span class=&quot;legendSpanClass&quot;&gt;&lt;person&gt;ST. GALLEN&lt;/person&gt;, &lt;location value=&quot;LC/ch&quot; idsrc=&quot;xmltag.org&quot; &gt;Switzerland&lt;/location&gt;&lt;/span&gt;, &lt;span class=&quot;legendSpanClass&quot;&gt;&lt;chron&gt;June 26, 2026&lt;/chron&gt;&lt;/span&gt; /PRNewswire/ -- &lt;span value=&quot;ACORN:4004701974&quot; idsrc=&quot;xmltag.org&quot; &gt;Vifor Fresenius Medical Care Renal Pharma&lt;/span&gt; (VFMCRP) and CSL announced today that the &lt;span value=&quot;ACORN:3106670068&quot; idsrc=&quot;xmltag.org&quot; &gt;European Medicines Agency's&lt;/span&gt; (EMA) &lt;span&gt;Committee for Medicinal Products&lt;/span&gt; for Human Use (CHMP) has recommended the revocation of the &lt;span&gt;European Union&lt;/span&gt; (EU) marketing authorisation for TAVNEOS® (avacopan). TAVNEOS is a treatment for adults with severe, active granulomatosis with polyangiitis (GPA) or microscopic polyangiitis (MPA), which are the main forms of ANCA-associated vasculitis. TAVNEOS</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Press+Releases/CHMP+recommends+revoking+marketing+authorisation+for+TAVNEOS%C2%AE+%28avacopan%29+in+the+European+Union/26695514.html</guid>
   <pubDate>Fri, 26 Jun 2026 09:00:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">A.01699993</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.31066700</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.37879753</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.40047019</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.60012004</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">CSL</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">CSLLY</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.00185691</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.00222426</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.00673957</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.01304637</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.09767912</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.22422661</category>
   	  </item>
  <item>
   <title>CHMP recommends revoking marketing authorisation for TAVNEOS® (avacopan) in the European Union</title>
   <link>http://www.streetinsider.com/Press+Releases/CHMP+recommends+revoking+marketing+authorisation+for+TAVNEOS%C2%AE+%28avacopan%29+in+the+European+Union/26695514.html</link>
   <description>
&lt;div class=&quot;xn-content&quot;&gt;
&lt;ul type=&quot;disc&quot;&gt;&lt;li&gt;Recommendation follows an Article 20 non-pharmacovigilance procedure &lt;/li&gt;&lt;li&gt;Patients currently on TAVNEOS treatment should consult their treating physician  &lt;/li&gt;&lt;/ul&gt;&lt;p&gt;&lt;span class=&quot;legendSpanClass&quot;&gt;&lt;person&gt;ST. GALLEN&lt;/person&gt;, &lt;location value=&quot;LC/ch&quot; idsrc=&quot;xmltag.org&quot; &gt;Switzerland&lt;/location&gt;&lt;/span&gt;, &lt;span class=&quot;legendSpanClass&quot;&gt;&lt;chron&gt;June 26, 2026&lt;/chron&gt;&lt;/span&gt; /PRNewswire/ -- &lt;span value=&quot;ACORN:4004701974&quot; idsrc=&quot;xmltag.org&quot; &gt;Vifor Fresenius Medical Care Renal Pharma&lt;/span&gt; (VFMCRP) and CSL announced today that the &lt;span value=&quot;ACORN:3106670068&quot; idsrc=&quot;xmltag.org&quot; &gt;European Medicines Agency's&lt;/span&gt; (EMA) &lt;span&gt;Committee for Medicinal Products&lt;/span&gt; for Human Use (CHMP) has recommended the revocation of the &lt;span&gt;European Union&lt;/span&gt; (EU) marketing authorisation for TAVNEOS® (avacopan). TAVNEOS is a treatment for adults with severe, active granulomatosis with polyangiitis (GPA) or microscopic polyangiitis (MPA), which are the main forms of ANCA-associated vasculitis. TAVNEOS</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Press+Releases/CHMP+recommends+revoking+marketing+authorisation+for+TAVNEOS%C2%AE+%28avacopan%29+in+the+European+Union/26695514.html</guid>
   <pubDate>Fri, 26 Jun 2026 09:00:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">A.01699993</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.31066700</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.37879753</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.40047019</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.60012004</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">CSL</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">CSLLY</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.00185691</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.00222426</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.00673957</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.01304637</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.09767912</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.22422661</category>
   	  </item>
  <item>
   <title>CHMP recommends revoking marketing authorisation for TAVNEOS® (avacopan) in the European Union</title>
   <link>http://www.streetinsider.com/Press+Releases/CHMP+recommends+revoking+marketing+authorisation+for+TAVNEOS%C2%AE+%28avacopan%29+in+the+European+Union/26695514.html</link>
   <description>
&lt;div class=&quot;xn-content&quot;&gt;
&lt;ul type=&quot;disc&quot;&gt;&lt;li&gt;Recommendation follows an Article 20 non-pharmacovigilance procedure &lt;/li&gt;&lt;li&gt;Patients currently on TAVNEOS treatment should consult their treating physician  &lt;/li&gt;&lt;/ul&gt;&lt;p&gt;&lt;span class=&quot;legendSpanClass&quot;&gt;&lt;person&gt;ST. GALLEN&lt;/person&gt;, &lt;location value=&quot;LC/ch&quot; idsrc=&quot;xmltag.org&quot; &gt;Switzerland&lt;/location&gt;&lt;/span&gt;, &lt;span class=&quot;legendSpanClass&quot;&gt;&lt;chron&gt;June 26, 2026&lt;/chron&gt;&lt;/span&gt; /PRNewswire/ -- &lt;span value=&quot;ACORN:4004701974&quot; idsrc=&quot;xmltag.org&quot; &gt;Vifor Fresenius Medical Care Renal Pharma&lt;/span&gt; (VFMCRP) and CSL announced today that the &lt;span value=&quot;ACORN:3106670068&quot; idsrc=&quot;xmltag.org&quot; &gt;European Medicines Agency's&lt;/span&gt; (EMA) &lt;span&gt;Committee for Medicinal Products&lt;/span&gt; for Human Use (CHMP) has recommended the revocation of the &lt;span&gt;European Union&lt;/span&gt; (EU) marketing authorisation for TAVNEOS® (avacopan). TAVNEOS is a treatment for adults with severe, active granulomatosis with polyangiitis (GPA) or microscopic polyangiitis (MPA), which are the main forms of ANCA-associated vasculitis. TAVNEOS</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Press+Releases/CHMP+recommends+revoking+marketing+authorisation+for+TAVNEOS%C2%AE+%28avacopan%29+in+the+European+Union/26695514.html</guid>
   <pubDate>Fri, 26 Jun 2026 09:00:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">A.01699993</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.31066700</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.37879753</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.40047019</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.60012004</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">CSL</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">CSLLY</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.00185691</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.00222426</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.00673957</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.01304637</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.09767912</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.22422661</category>
   	  </item>
 </channel>
</rss>
